Navigation Links
Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
Date:12/17/2008

EMERYVILLE, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced that an independent Data Safety Monitoring Board (DSMB) has determined that the current clinical trials of Viprinex(TM) for the treatment of acute ischemic stroke are unlikely to show benefit. As a result, the company has terminated further enrollment in the trials. NTI will obtain and analyze the data before evaluating the potential for any future development of Viprinex. The interim analysis conducted by the DSMB evaluated stroke patients' outcome 90 days following an acute ischemic stroke, comparing treatment with Viprinex to treatment with placebo. The DSMB determined that there was no clinically meaningful difference in outcome between the two treatment groups as measured on the modified Rankin scale of disability, the primary endpoint of the study.

"We are deeply disappointed that Viprinex did not improve overall patient outcomes in our clinical study," said Paul E. Freiman, president and chief executive officer. "This news is a significant set-back for our clinical program. Once we obtain the data and we have analyzed the results from this study, which we expect to occur in early 2009, we will determine whether we will pursue any further development of Viprinex. In the meantime, we are implementing plans we have developed to reduce our expenses, which will likely result in a significant reduction in our overall headcount if we determine that future development of Viprinex is not warranted."

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
2. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
3. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
4. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
5. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
6. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
7. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
8. ImmunoVaccine Technologies DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases
9. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
10. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
11. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... BCC Research report discusses the medical device technologies in terms ... and opportunities for different devices and regions. It includes forecasts ... the report focuses on technological trends in recent years in ... and Japan . Use ... device technologies market. - Analyze market structure, including segments and ...
(Date:9/18/2014)...  Iliad Neurosciences, Inc., a company focused on the ... Spectrum Disorders (ASD) announced today that it has entered ... for The State University of New York. ... to identify an abnormality in folate transport to the ... expected to be available for research use by physicians ...
(Date:9/18/2014)... , September 18, 2014 ... has updated the incredibly successful Serialisation Countdown calendar to ... PDF, available at pharmaserialisation.com shows the serialisation ... they will be coming into force. For ... a matter of "if", but "when" they will have ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2
... Annual Superbugs and Superdrugs Conference on ... ... Enanta Pharmaceuticals, a,leader in the development of small molecule ... to,evaluate a new macrolide-related drug class, Bicyclolides, in the treatment,of ...
... to collaborate on latest research technologies, ALBUQUERQUE, ... Inc. (OTC Bulletin Board: BMOD),( http://www.biomoda.com ), a ... entitled "New Non-Invasive Technology for the Early,Detection of ... Annual,Multidisciplinary Meeting of the American Association for the ...
Cached Medicine Technology:Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA 2Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA 3Biomoda to Present Paper on Enhanced Technology for Early Detection of Lung Cancer at Annual SWARM Meeting 2
(Date:9/18/2014)... 2014 TayganPoint Consulting Group, a ... President and co-founder John Cassimatis was named as ... for 2014, recognizing the region’s top healthcare and ... executive of the year. , The Innovation Awards ... that continue to shape the medical industry in ...
(Date:9/18/2014)... microbes -- don,t worry, it,s a good thing! As ... microbes are bad. Many active enzymes and bacteria are ... as an important part of our digestive system or ... albicans , an opportunistic yeast pathogen and model organism ... healthy personal ecosystem. However, when our immune system is ...
(Date:9/18/2014)... elderly men should not be routinely screened for prostate ... new study led by researchers at Henry Ford Hospital., ... JAMA Internal Medicine , focused on the use ... prostate cancer., "We found that the effect of the ... in particular has been minimal at best," says Jesse ...
(Date:9/18/2014)... York, New York (PRWEB) September 18, 2014 ... ) continue to mount in U.S. courts, Bernstein ... has recommended that the U.S. Food & Drug ... new restrictions that, if implemented, could greatly reduce ... Bone, Reproductive and Urologic Drug Advisory Committee, and ...
(Date:9/18/2014)... News) -- Teens and young adults who,ve been mentored ... provides them with greater responsibility and independence early on ... "We found that having a mentor provides a clear ... author, Steve McDonald, an associate professor of sociology at ... release. In conducting the study, published online ...
Breaking Medicine News(10 mins):Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 3Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 4Health News: Mentors May Steer Young People Toward More Rewarding Careers 2
... approach to treatment that focuses on recovery from mental ... acclaim for the Medical College of Georgia Department of ... Project GREAT, or the Georgia Recovery-Based Educational Approach ... to be part of their own care, while also ...
... FRIDAY, Feb. 24 (HealthDay News) -- Sudden Infant Death Syndrome ... German researchers reports. DNA analysis from a small group ... the male children carried a particular enzyme mutation that may ... the case for female SIDS patients. Study author Dr. ...
... Overweight or obese people with chronic kidney disease may suffer ... new study warns. Cleveland Clinic researchers analyzed the eating ... who took part in the U.S. National Health and Nutrition ... percent said they had tried to lose weight in the ...
... Serena Gordon HealthDay Reporter , FRIDAY, Feb. 24 ... on their own take a companion -- usually a spouse ... office visits, researchers report. And they tend to bring ... health care system with another important member of a patient,s ...
... , This release is available in Spanish ... and the university hospital Virgen de las Nieves in Granada ... toxic than that traditionally used and only targets cancerous tissue. ... efficient cancer postoperative treatment for cases of cancer of the ...
... Cells that die naturally generate a lot of internal debris ... leading to diseases such as lupus., Now Georgia Health Sciences ... a woman,s immune system from attacking a fetus also helps ... such as DNA or joints. , The findings point ...
Cached Medicine News:Health News:Psychiatry program garners national education award 2Health News:Psychiatry program garners national education award 3Health News:Gene Might Be a Culprit in Sudden Infant Death for Boys 2Health News:Gene Might Be a Culprit in Sudden Infant Death for Boys 3Health News:Dieting Can Prove Dangerous for Kidney Disease Patients 2Health News:Many Elderly Now Bring Companion on Doctor's Visit 2Health News:Many Elderly Now Bring Companion on Doctor's Visit 3Health News:A new radiotherapy technique significantly reduces irradiation of healthy tissue 2Health News:Natural method for clearing cellular debris provides new targets for lupus treatment 2Health News:Natural method for clearing cellular debris provides new targets for lupus treatment 3
3 mm diameter roller blade, 15 mm from angle to tip. Round handle....
2 mm wide x 3 mm long, with rounded triangular tip. Angled 45 degrees. Hexagonal handle....
Duckbill type sharp. 3 mm wide x 8 mm long curved blade. Octagonal handle....
9 mm slightly curved blade. Hexagonal handle....
Medicine Products: